查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953930

肺部治療市場－全球產業規模、佔有率、趨勢、機會及預測（依疾病類型、治療類型、藥物類別、地區及競爭格局分類，2021-2031年）

Lung Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Treatment Type, By Drug Class, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肺部疾病藥物市場預計將從 2025 年的 1,042.6 億美元成長到 2031 年的 1,473.1 億美元，複合年成長率達到 5.93%。

此細分市場包括用於治療氣喘、慢性阻塞性肺病和肺纖維化等呼吸系統疾病的藥品和生物製藥，例如支氣管擴張劑和皮質類固醇。市場擴張的主要促進因素是呼吸系統疾病發生率的上升，而這又歸因於快速的都市化、日益嚴重的環境污染以及人口老化（老年人更容易患慢性病）。美國肺臟協會強調了環境因素的影響，其報告指出，到2024年，美國約有1.31億人將居住在空氣污染水平不健康的地區，凸顯了有效呼吸系統治療的緊迫性。

市場概覽
預測期 2027-2031
市場規模：2025年 1042.6億美元
市場規模：2031年 1473.1億美元
複合年成長率：2026-2031年 5.93%
成長最快的細分市場 化療
最大的市場 北美洲

儘管前景廣闊，但由於研發和生產複雜生物藥物需要巨額資金，市場仍面臨許多障礙。這些高昂的研發成本，加上嚴格的監管核准流程，往往會延緩新治療方法的上市，並限制價格敏感型市場患者的用藥機會，從而阻礙全球治療行業的全面發展。

市場促進因素

在全球範圍內，因持續吸煙導致的慢性呼吸系統疾病日益增多，這已成為治療藥物市場的主要驅動力。吸菸會顯著損害肺功能，導致慢性阻塞性肺病（COPD）等疾病，這些疾病需要長期藥物治療。尼古丁的成癮性維持了這種需求。正如世界衛生組織（世衛組織）2024年5月發布的《菸草》關鍵情況說明書中所述，菸草每年導致超過800萬人死亡，其中包括130萬因二手菸而死亡的非吸菸者。因此，吸菸相關疾病的負擔迫切需要我們持續研發治療方法，以控制症狀並改善患者健康。

此外，生物製藥和標靶治療的技術進步正在改變呼吸系統疾病的治療格局，為難以控制的呼吸系統疾病提供超越傳統症狀管理的解決方案。這些先進的生物製藥可針對治療重度氣喘和慢性阻塞性肺病（COPD）等疾病中的特定發炎通路，顯著降低病情加重率和住院率。例如，再生元製藥公司在2024年9月的新聞稿中宣布，其生物製藥可將COPD患者的中重度病情加重率降低34%。這種向精準醫療的轉變得到了大量產業投資的支持，例如Astra Zeneca在2024年宣布，將投資15大規模美元在新加坡建造一座專門用於抗體藥物複合體和標靶治療的工廠。

市場挑戰

開發和生產複雜生物製藥所需的大量資本支出和嚴格的監管核准流程，對全球肺部治療領域的進步構成了重大障礙。臨床研究和專業生產所需的巨額投資迫使製藥公司對先進治療方法進行極具競爭力的定價以收回成本。這限制了其在對成本敏感地區的市場滲透率，並使許多患者無法獲得治療。此外，這些投資帶來的巨大財務風險也阻礙了小眾市場或高風險呼吸系統疾病新型作用機制的研究，有效扼殺了創新。

最新的產業數據顯示，這一巨大的經濟負擔凸顯了該領域面臨的盈利挑戰。根據國際藥品製造商協會聯合會（IFPMA）2024年的數據，新藥研發的平均成本預計已達26億美元。如此巨額的成本直接阻礙了市場擴張，提高了准入門檻，延緩了創新生物製藥的上市進程，而這些藥物對於治療氣喘和慢性阻塞性肺病等疾病至關重要。

市場趨勢

智慧吸入器和互聯數位療法的引入正在改變患者照護，提高用藥依從性並提供即時生理數據。這些技術利用感測器設備監測使用模式和吸氣流量，使醫療專業人員能夠客製化干涉措施，避免慢性呼吸系統疾病的加重。互聯醫療領域強勁的財務表現也支撐了這一數位轉型。例如，在2024年8月的公佈財報上，ResMed公司報告稱，其營收成長9%至12億美元，這主要得益於市場對其雲端連接睡眠和呼吸照護解決方案的持續需求。

同時，針對罕見呼吸系統疾病的疾病修正治療正日益受到關注，治療重點也從緩解症狀轉向標靶化潛在的基因缺陷。製藥公司正大力投資小分子矯正劑和增強劑，以糾正囊腫纖維化等疾病中的特定蛋白質功能障礙，從而顯著改善肺功能和患者存活率。這一策略方向也體現在市場領導的財務成功上。 Vertex Pharmaceuticals 在 2024 年 11 月的報告中宣布，其產品收入成長 12%，達到 27.7 億美元，這主要得益於該公司專門針對囊腫纖維化的療法在全球範圍內的廣泛應用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球肺部疾病藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依疾病類型（氣喘、肺癌、慢性阻塞性肺病）
    • 依治療方法（化療、免疫療法、標靶治療、放射線治療）
    • 依藥物類別（皮質類固醇、支氣管擴張劑、抗生素、烷化劑、祛痰藥）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肺部藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲肺部藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區肺部藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲肺部疾病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美肺病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球肺部藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Allergan Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F Hoffmann-La Roche Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23921

The Global Lung Disease Therapeutics Market is projected to expand from USD 104.26 Billion in 2025 to USD 147.31 Billion by 2031, achieving a compound annual growth rate of 5.93%. This sector comprises pharmaceutical formulations and biological agents, including bronchodilators and corticosteroids, intended to treat respiratory pathologies such as asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis. Market expansion is chiefly driven by the rising incidence of respiratory disorders caused by rapid urbanization, escalating environmental pollution, and a growing aging population prone to chronic ailments. Highlighting the impact of environmental factors, the American Lung Association reported in 2024 that approximately 131 million people in the United States resided in areas with unhealthy air pollution levels, emphasizing the urgent need for effective respiratory treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 104.26 Billion
Market Size 2031USD 147.31 Billion
CAGR 2026-20315.93%
Fastest Growing SegmentChemotherapy
Largest MarketNorth America

Despite these growth prospects, the market confronts a major obstacle regarding the immense capital needed to develop and manufacture complex biologic drugs. These significant development expenditures, combined with strict regulatory approval processes, often postpone the launch of new therapies and restrict patient access in price-sensitive markets, thereby impeding the broader growth of the global therapeutics industry.

Market Driver

The increasing global prevalence of chronic respiratory diseases, driven by ongoing tobacco use, acts as a primary catalyst for the therapeutics market. Smoking severely impairs lung function, resulting in conditions like chronic obstructive pulmonary disease that require prolonged pharmacological intervention, a demand sustained by the addictive nature of nicotine. As noted in the World Health Organization's 'Tobacco' key facts sheet from May 2024, tobacco causes over 8 million deaths annually, including 1.3 million non-smokers affected by second-hand smoke; consequently, the smoking-related disease burden necessitates the continual development of therapeutic measures to manage symptoms and enhance patient well-being.

Furthermore, technological progress in biologics and targeted therapies is transforming the treatment landscape by providing solutions for uncontrolled respiratory conditions that go beyond traditional symptom management. These advanced biologics target specific inflammatory pathways in diseases like severe asthma and chronic obstructive pulmonary disease, significantly lowering exacerbation rates and hospitalizations. For instance, Regeneron Pharmaceuticals announced in a September 2024 press release that their biologic reduced moderate-to-severe exacerbation rates by 34 percent in COPD patients. This move toward precision medicine is backed by massive industrial investment, such as AstraZeneca's 2024 announcement of a USD 1.5 billion investment to build a Singapore facility dedicated to antibody-drug conjugates and targeted therapies.

Market Challenge

The substantial capital required for developing and manufacturing complex biologic drugs, along with stringent regulatory approval procedures, presents a significant barrier to the advancement of the global lung disease therapeutics sector. The immense financial outlay necessary for clinical research and specialized production compels pharmaceutical firms to set premium prices for advanced therapies to recoup costs, which limits market penetration in cost-sensitive areas and restricts access for many patients. Additionally, the considerable financial risks involved in these investments deter the pursuit of novel mechanisms of action for respiratory pathologies with smaller or riskier markets, effectively stalling innovation.

The severity of this financial burden is highlighted by recent industry data, which underscores the high threshold for profitability in the sector. According to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in 2024, the estimated average cost to develop a new medicine reached USD 2.6 billion. This enormous expense directly hinders market expansion by raising the barrier to entry and slowing the introduction of innovative biologics essential for treating conditions such as asthma and chronic obstructive pulmonary disease.

Market Trends

The incorporation of smart inhalers and connected digital therapeutics is transforming patient care by improving medication adherence and supplying real-time physiological insights. These technologies employ sensor-enabled devices to monitor usage patterns and inspiratory flow, enabling healthcare professionals to customize interventions and avert exacerbations in chronic respiratory conditions. This digital shift is validated by robust financial results in the connected care domain; for example, ResMed reported in its August 2024 earnings release that revenue grew by 9 percent to USD 1.2 billion, fueled by persistent demand for its cloud-connected sleep and respiratory care solutions.

Concurrently, there is a heightened emphasis on disease-modifying therapies for rare respiratory disorders, transitioning the treatment focus from symptomatic relief to targeting root genetic defects. Pharmaceutical companies are heavily investing in small molecule correctors and potentiators that rectify specific protein malfunctions in conditions like cystic fibrosis, thereby significantly enhancing lung function and patient survival. This strategic direction is reflected in the financial success of market leaders; Vertex Pharmaceuticals, in its November 2024 report, announced a 12 percent increase in product revenue to USD 2.77 billion, largely driven by the widespread global adoption of its specialized cystic fibrosis treatments.

Key Market Players

  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Allergan Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F Hoffmann-La Roche Ltd.

Report Scope

In this report, the Global Lung Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Disease Therapeutics Market, By Disease Type

  • Asthma
  • Lung Cancer
  • Chronic Obstructive Pulmonary Disease

Lung Disease Therapeutics Market, By Treatment Type

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy

Lung Disease Therapeutics Market, By Drug Class

  • Corticosteroids
  • Bronchodilator
  • Antimicrobial
  • Alkylating Agents
  • Mucolytics

Lung Disease Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Disease Therapeutics Market.

Available Customizations:

Global Lung Disease Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Disease Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Asthma, Lung Cancer, Chronic Obstructive Pulmonary Disease)
    • 5.2.2. By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy)
    • 5.2.3. By Drug Class (Corticosteroids, Bronchodilator, Antimicrobial, Alkylating Agents, Mucolytics)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Lung Disease Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By Drug Class
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Lung Disease Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Treatment Type
        • 6.3.1.2.3. By Drug Class
    • 6.3.2. Canada Lung Disease Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Treatment Type
        • 6.3.2.2.3. By Drug Class
    • 6.3.3. Mexico Lung Disease Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Treatment Type
        • 6.3.3.2.3. By Drug Class

7. Europe Lung Disease Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Drug Class
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Lung Disease Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By Drug Class
    • 7.3.2. France Lung Disease Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By Drug Class
    • 7.3.3. United Kingdom Lung Disease Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By Drug Class
    • 7.3.4. Italy Lung Disease Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Treatment Type
        • 7.3.4.2.3. By Drug Class
    • 7.3.5. Spain Lung Disease Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Treatment Type
        • 7.3.5.2.3. By Drug Class

8. Asia Pacific Lung Disease Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Drug Class
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Lung Disease Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By Drug Class
    • 8.3.2. India Lung Disease Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By Drug Class
    • 8.3.3. Japan Lung Disease Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By Drug Class
    • 8.3.4. South Korea Lung Disease Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Treatment Type
        • 8.3.4.2.3. By Drug Class
    • 8.3.5. Australia Lung Disease Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Treatment Type
        • 8.3.5.2.3. By Drug Class

9. Middle East & Africa Lung Disease Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Drug Class
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Lung Disease Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By Drug Class
    • 9.3.2. UAE Lung Disease Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By Drug Class
    • 9.3.3. South Africa Lung Disease Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By Drug Class

10. South America Lung Disease Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By Drug Class
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Lung Disease Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Treatment Type
        • 10.3.1.2.3. By Drug Class
    • 10.3.2. Colombia Lung Disease Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Treatment Type
        • 10.3.2.2.3. By Drug Class
    • 10.3.3. Argentina Lung Disease Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Treatment Type
        • 10.3.3.2.3. By Drug Class

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Lung Disease Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Johnson & Johnson Services, Inc.
  • 15.3. Amgen Inc.
  • 15.4. AstraZeneca Plc
  • 15.5. Boehringer Ingelheim International GmbH
  • 15.6. Pfizer Inc.
  • 15.7. Allergan Inc.
  • 15.8. Bristol-Myers Squibb Company
  • 15.9. Eli Lilly and Company
  • 15.10. F Hoffmann-La Roche Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer